Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 1
1972 31
1973 24
1974 23
1975 30
1976 30
1977 28
1978 23
1979 23
1980 23
1981 37
1982 51
1983 61
1984 110
1985 112
1986 92
1987 75
1988 66
1989 77
1990 75
1991 57
1992 65
1993 72
1994 63
1995 57
1996 41
1997 67
1998 59
1999 58
2000 86
2001 118
2002 119
2003 169
2004 164
2005 218
2006 256
2007 267
2008 267
2009 356
2010 369
2011 426
2012 523
2013 526
2014 537
2015 474
2016 438
2017 462
2018 387
2019 424
2020 299
2021 53
Text availability
Article attribute
Article type
Publication date

Search Results

7,641 results
Results by year
Filters applied: . Clear all
Page 1
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR, Scott BL, Boyd T, Garcia-Manero G. Cogle CR, et al. Oncologist. 2015 Dec;20(12):1404-12. doi: 10.1634/theoncologist.2015-0165. Epub 2015 Oct 13. Oncologist. 2015. PMID: 26463870 Free PMC article. Review.
Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. ...This review presents clinical data supporting the use of injectable azacitidine in MDS and AML and examines the rationale for and results …
Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. ...This …
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Almasri J, Alkhateeb HB, Firwana B, Sonbol MB, Damlaj M, Wang Z, Murad MH, Al-Kali A. Almasri J, et al. Syst Rev. 2018 Sep 19;7(1):144. doi: 10.1186/s13643-018-0805-7. Syst Rev. 2018. PMID: 30227896 Free PMC article.
BACKGROUND: Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndromes (MDS). ...CONCLUSIONS: Azacitidine and decitabine are both associated with improved outcomes compared to BSC. ...
BACKGROUND: Hypomethylating agents (HMA), azacitidine, and decitabine are frequently used in the management of myelodysplastic syndro …
5-Azacytidine/Azacitidine.
Müller A, Florek M. Müller A, et al. Recent Results Cancer Res. 2010;184:159-70. doi: 10.1007/978-3-642-01222-8_11. Recent Results Cancer Res. 2010. PMID: 20072837 Review.
Azacitidine.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1990;50:47-63. IARC Monogr Eval Carcinog Risks Hum. 1990. PMID: 1705587 Free PMC article. Review. No abstract available.
Azacitidine.
National Toxicology Program. National Toxicology Program. Rep Carcinog. 2011;12:56-7. Rep Carcinog. 2011. PMID: 21829253 Free article. No abstract available.
Azacitidine.
Issa JP, Kantarjian HM, Kirkpatrick P. Issa JP, et al. Nat Rev Drug Discov. 2005 Apr;4(4):275-6. doi: 10.1038/nrd1698. Nat Rev Drug Discov. 2005. PMID: 15861567 No abstract available.
Azacitidine.
[No authors listed] [No authors listed] Rep Carcinog. 2004;11:III24-5. Rep Carcinog. 2004. PMID: 21089806 No abstract available.
Azacitidine: in myelodysplastic syndromes.
Siddiqui MA, Scott LJ. Siddiqui MA, et al. Drugs. 2005;65(13):1781-9; discussion 1790-1. doi: 10.2165/00003495-200565130-00004. Drugs. 2005. PMID: 16114977 Review.
Patients (n=49) who were switched from supportive care to azacitidine after 4 months also showed a 47% response rate. The clinical response in patients receiving azacitidine was associated with significant (p<or=0.015) improvements in several measures of health-r …
Patients (n=49) who were switched from supportive care to azacitidine after 4 months also showed a 47% response rate. The clinical re …
The role of azacitidine in the treatment of myelodysplastic syndromes.
Abdulhaq H, Rossetti JM. Abdulhaq H, et al. Expert Opin Investig Drugs. 2007 Dec;16(12):1967-75. doi: 10.1517/13543784.16.12.1967. Expert Opin Investig Drugs. 2007. PMID: 18042004 Review.
Azacitidine was the first agent noted to change the natural history of the disease. ...Azacitidine is also likely to be studied in the treatment of other malignant conditions. ...
Azacitidine was the first agent noted to change the natural history of the disease. ...Azacitidine is also likely to be studie
Azacitidine: a novel agent for myelodysplastic syndromes.
Sullivan M, Hahn K, Kolesar JM. Sullivan M, et al. Am J Health Syst Pharm. 2005 Aug 1;62(15):1567-73. doi: 10.2146/ajhp040385. Am J Health Syst Pharm. 2005. PMID: 16030365 Review.
Azacitidine is available as sterile lyophilized powder in single-use vials for reconstitution. The recommended dosage of azacitidine for the first treatment cycle is 75 mg/m(2) daily for seven days. ...
Azacitidine is available as sterile lyophilized powder in single-use vials for reconstitution. The recommended dosage of azacitidi
7,641 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page